In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Waites, Ken B ^a   Crabb, Donna M ^a   Duffy, Lynn B ^a   Jensen, Jorgen S ^b   Liu, Yang ^c   Paukner, Susanne ^d  

^a University of Alabama at Birmingham   (United States)

^b STATENS SERUM INSTITUT   (Denmark)

^c FUDAN UNIVERSITY   (China)

^d Nabriva Therapeutics Inc   (Austria)

Author keywords

Lefamulin; Mycoplasma pneumoniae; Pleuromutilin; Pneumonia; Susceptibility testing

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEFAMULIN; MACROLIDE; MOXIFLOXACIN; SOLITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; DITERPENE; PLEUROMUTILIN; QUINOLONE DERIVATIVE;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CHINA; CONTROLLED STUDY; DILUTION; EUROPE; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; UNITED STATES; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHINA; DITERPENES; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; EUROPE; FLUOROQUINOLONES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA PNEUMONIAE; UNITED STATES;

EID: 85010955787     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02008-16     Document Type: Article

References (22)

1. Waites KB, Talkington DF. 2004. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17:697-728. https://doi.org/10.1128/CMR.17.4.697-728.2004.
2. Lucier TS, Heitzman K, Liu SK, Hu PC. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 39:2770-2773. https://doi.org/10.1128/AAC.39.12.2770.
3. Bebear C, Pereyre S, Peuchant O. 2011. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 6:423-431. https://doi.org/10.2217/fmb.11.18.
4. Woese CR, Stackebrandt E, Ludwig W. 1984. What are mycoplasmas: the relationship of tempo and mode in bacterial evolution. J Mol Evol 21:305-316.
5. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, Meng F, Zhu L, Lv M, Yin Y, Zhang J. 2013. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother 57:1521-1523. https://doi.org/10.1128/AAC.02060-12.
6. Yamamoto T, Kida Y, Sakamoto Y, Kuwano K. 2016. Mpn491, a secreted nuclease of Mycoplasma pneumoniae, plays a critical role in evading killing by neutrophil extracellular traps. Cell Microbiol. https://doi.org/10.1111/cmi.12666.
7. Dumke R, Luck C, Jacobs E. 2013. Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012. Antimicrob Agents Chemother 57:3460. https://doi.org/10.1128/AAC.00706-13.
8. Pereyre S, Touati A, Petitjean-Lecherbonnier J, Charron A, Vabret A, Bebear C. 2013. The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clin Microbiol Infect 19:E212-E217. https://doi.org/10.1111/1469-0691.12107.
9. Ferguson GD, Gadsby NJ, Henderson SS, Hardie A, Kalima P, Morris AC, Hill AT, Cunningham S, Templeton KE. 2013. Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J Med Microbiol 62:1876-1882. https://doi.org/10.1099/jmm.0.066191-0.
10. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, Valzano A, Esposito S. 2011. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J 37:1522-1524. https://doi.org/10.1183/09031936.00172510.
11. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. 2011. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 17:1079-1082. https://doi.org/10.3201/eid/1706.101558.
12. Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, Hong T, Todd K, Ratliff AE, Crabb DM, Xiao L, Atkinson TP, Waites KB. 2015. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 21:1470-1472. https://doi.org/10.3201/eid2108.150273.
13. Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN. 2013. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother 57:4489-4495. https://doi.org/10.1128/AAC.00358-13.
14. Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS. 2016. In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob Agents Chemother 60:4407-4411. https://doi.org/10.1128/AAC.00627-16.
15. Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother 67:1170-1175. https://doi.org/10.1093/jac/dks001.
16. Clinical and Laboratory Standards Institute. 2011. Methods for Antimicrobial susceptibility testing of human mycoplasmas; approved guideline. CLSI document M43-A. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Waites KB, Bebear CM, Robertson JA, Talkington DF, Kenny GE. 2001. Cumitech 34, laboratory diagnosis of mycoplasmal infections. In Nolte FS (coordinating ed). ASM Press, Washington, DC.
18. Waites KB, Crabb DM, Duffy LB. 2009. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 53:2139-2141. https://doi.org/10.1128/AAC.00090-09.
19. Waites KB, Lysynyansky I, Bebear CM. 2014. Emerging antimicrobial resistance in mycoplasmas of humans and animals, p 289-322. In Browning G, Citti C (ed), Mollicutes molecular biology and pathogenesis. Caister Academic Press, Norfolk, UK.
20. Heilmann C, Jensen L, Jensen JS, Lundstrom K, Windsor D, Windsor H, Webster D. 2001. Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect 43:234-238. https://doi.org/10.1053/jinf.2001.0910.
21. Hannan PC, Windsor HM, Ripley PH. 1997. In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae. Res Vet Sci 63:157-160. https://doi.org/10.1016/S0034-5288(97)90010-2.
22. Li BB, Shen JZ, Cao XY, Wang Y, Dai L, Huang SY, Wu CM. 2010. Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum. FEMS Microbiol Lett 308:144-149. https://doi.org/10.1111/j.1574-6968.2010.02003.x.